Uncover the actionable breast cancer insights you need—when you need them.

Looking to predict individual chemotherapy benefit?

The Oncotype DX Breast Recurrence Score^® test can help determine whether an individual diagnosed with early-stage HR+, HER2- breast cancer may benefit from chemotherapy and to quantify their individual risk of recurrence.*

Looking to identify hereditary cancer risk?

The Riskguard^® test can assist with informing an individualized plan, including targeted therapies, surgical treatment planning, and increased surveillance for additional primary cancers.

Looking for a more comprehensive treatment plan?

Pair the Riskguard test with the Oncotype DX Breast Recurrence Score test to help inform a more comprehensive treatment plan for newly diagnosed HR+, HER2- breast cancer patients.

Exact Sciences’ comprehensive testing portfolio can help provide critical insights and treatment guidance across all solid tumors. Visit us at Booth #943 to learn more.

*Paik et al. N Engl J Med. 2004;351(27):2817-2826; Paik et al. J Clin Oncol. 2006;24(23):3726-3734; Dowsett et al. J Clin Oncol. 2010;28(11):1829-1834; Albain et al. Lancet Oncol. 2010;11(1):55-65 Kalinsky; et al. N Engl J Med. 2021;385(25):2336-2347; Sparano et al. NEJM Evid. 2024;3(8):EVIDoa2300267.